Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 31 · below the Ichimoku cloud · RSI 33 · MACD below its signal · at its 52-week low
None of the 29 investors followed here reported a position in REVB in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a REVB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 16, 2026 | Chawla Lakhmir SDirector | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| Aug 16, 2026 | Carver Jennifer ADirector | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| Aug 16, 2026 | Rolke James MChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 208.1K | — |
| Aug 16, 2026 | Zygmont Chester Stanley IiiChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 208.1K | — |
| Aug 16, 2026 | Roper JessDirector | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| Aug 16, 2026 | Zygmont Chester Stanley IiiChief Financial Officer | Stock Gift at price 0.00 per share. | 208.1K | — |
| Jan 7, 2026 | Chawla Lakhmir SDirector | Stock Award(Grant) at price 0.90 per share. | 42K | $37.78K |
| Jan 7, 2026 | Carver Jennifer ADirector | Stock Award(Grant) at price 0.90 per share. | 42K | $37.78K |
| Jan 7, 2026 | Rolke James MChief Executive Officer | Stock Award(Grant) at price 0.90 per share. | 532.8K | $479.55K |
| Jan 7, 2026 | Zygmont Chester Stanley IiiChief Financial Officer | Stock Award(Grant) at price 0.90 per share. | 78.1K | $70.33K |
| Jan 7, 2026 | Roper JessDirector | Stock Award(Grant) at price 0.90 per share. | 42K | $37.78K |
| Oct 28, 2025 | Chawla Lakhmir SDirector | Stock Award(Grant) at price 1.28 per share. | 15.6K | $20.00K |
| Oct 28, 2025 | Carver Jennifer ADirector | Stock Award(Grant) at price 1.28 per share. | 15.6K | $20.00K |
| Oct 28, 2025 | Rolke James MChief Executive Officer | Stock Award(Grant) at price 1.28 per share. | 390.6K | $499.99K |
| Oct 28, 2025 | Zygmont Chester Stanley IiiChief Financial Officer | Stock Award(Grant) at price 1.28 per share. | 390.6K | $499.99K |
| Oct 28, 2025 | Roper JessDirector | Stock Award(Grant) at price 1.28 per share. | 15.6K | $20.00K |
| Feb 10, 2025 | Tidmarsh George FDirector | Stock Award(Grant) at price 3.87 per share. | 181 | $700 |
| Feb 10, 2025 | Chawla Lakhmir SDirector | Stock Award(Grant) at price 3.87 per share. | 181 | $700 |
| Feb 10, 2025 | Carver Jennifer ADirector | Stock Award(Grant) at price 3.87 per share. | 181 | $700 |
| Feb 10, 2025 | Rolke James MChief Executive Officer | Stock Award(Grant) at price 3.87 per share. | 30.1K | $116.47K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -36.6 | -35.0 | -9.1 | -5.8 | -3.1 | -5.9 | -7.8 | 5.3 | -18.3 | -10.6 | −77.2% | ||
| 2025 | -48.9 | -7.4 | -24.6 | 16.0 | -72.1 | -11.8 | 10.7 | 10.8 | -48.6 | -12.0 | -23.6 | -16.2 | −96.4% |
| 2024 | -41.5 | -58.5 | -24.9 | -23.1 | -8.4 | -1.0 | -13.6 | -30.3 | -25.9 | 0.1 | -10.9 | -39.3 | −96.9% |
| 2023 | 57.9 | -78.8 | -41.7 | -16.9 | -2.8 | -10.5 | -12.8 | -18.0 | 2.5 | -12.8 | 20.3 | -30.7 | −92.5% |
| 2022 | -75.4 | -48.6 | -11.6 | -16.7 | -44.7 | 111.4 | -49.3 | -29.3 | -34.4 | 10.3 | -30.6 | -5.0 | −98.1% |
| 2021 | 0.7 | 1.3 | -2.5 | 0.6 | -0.5 | 0.4 | -0.3 | 0.5 | 0.2 | 0.4 | 0.2 | 0.6 | +1.5% |
| 2020 | 0.6 | +0.6% |
Buy / hold / sell counts
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.